Edwards Lifesciences raised to buy from hold by Truist Securities, target price raised to $113 from $95
EW•Truist Securities raised its rating on Edwards Lifesciences to buy from hold and increased its target price to $113 from $95.
Related News
RBC cuts Ideaya Biosciences target price to $45 from $48
IDYA•
Piper Sandler raises AMD target price to $650 from $600
AMD•
Waters Corp: RBC raises target price to $525 from $475
WAT•
Thomson Reuters target price raised by National Bank of Canada to C$190 from C$180
TRI•
Thomson Reuters target price raised by Canaccord Genuity to $130.5 from $129.5
TRI•